{"DataElement":{"publicId":"3232840","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Follicular Percentage Range","preferredDefinition":"Numeric value to represent the percentage of the follicular component within the diffuse large B-cell lymphoma.","longName":"3232796v1.0:3232828v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3232796","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Follicular Lymphoma Percentage","preferredDefinition":"This non-Hodgkin's lymphoma is characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin's lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, T-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large B-cell lymphoma with expression of full-length ALK. (WHO, 2001) -- 2003_A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin's lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). -- 2003_Percentage; a fraction or ratio with 100 understood as the denominator.","longName":"2478319v1.0:3232794v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2478319","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","preferredDefinition":"This non-Hodgkin's lymphoma is characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin's lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, T-cell/histiocyte rich lymphoma, anaplastic lymphoma, plasmablastic lymphoma, and diffuse large B-cell lymphoma with expression of full-length ALK. (WHO, 2001) -- 2003","longName":"C8851","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11E01CB8-267E-253F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-20","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-04-20","modifiedBy":"ONEDATA","dateModified":"2006-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3232794","version":"1","preferredName":"Follicular Lymphoma Percentage","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin's lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). -- 2003:Percentage; a fraction or ratio with 100 understood as the denominator.","longName":"C3209:C25613","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8C99-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"ONEDATA","dateModified":"2011-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8CAA-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval by B. McClure-Shimel. mc 5/12/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3232828","version":"1","preferredName":"Follicular Lymphoma Percentage Range","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin's lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). -- 2003_Percentage; a fraction or ratio with 100 understood as the denominator._The difference between the lowest and highest numerical values; the limits or scale of variation.","longName":"3232828v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"> 10%","valueDescription":"> 10%","ValueMeaning":{"publicId":"3232829","version":"1","preferredName":"> 10%","longName":"3232829","preferredDefinition":"> 10%","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8D47-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2605BA7-8D60-4407-E040-BB89AD4335A4","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"ONEDATA","dateModified":"2011-05-03","deletedIndicator":"No"},{"value":"< or = 10%","valueDescription":"< or = 10%","ValueMeaning":{"publicId":"3232830","version":"1","preferredName":"< or = 10%","longName":"3232830","preferredDefinition":"< or = 10%","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8D6A-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A2605BA7-8D83-4407-E040-BB89AD4335A4","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"ONEDATA","dateModified":"2011-05-03","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DD7F6277-07CF-6BDD-E040-BB89AD434FC8","beginDate":"2013-05-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-24","modifiedBy":"ONEDATA","dateModified":"2013-05-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3232827","version":"1","preferredName":"Follicular Lymphoma Percentage Range","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin's lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001). -- 2003:Percentage; a fraction or ratio with 100 understood as the denominator.:The difference between the lowest and highest numerical values; the limits or scale of variation.","longName":"C3209:C25613:C38013","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Range","conceptCode":"C38013","definition":"The difference between the lowest and highest numerical values; the limits or scale of variation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8D21-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"ONEDATA","dateModified":"2011-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8D32-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"COOPERM","dateModified":"2013-05-24","changeDescription":"Released per approval by B. McClure-Shimel. mc 5/12/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"5655939","version":"1","longName":"BLGSP (Burkitt Lymphoma Genome Sequencing Project)","context":"OCG","ClassificationSchemeItems":[{"publicId":"10000269","version":"1","longName":"Enrollment Form","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"Percentage of Follicular Comp","type":"Preferred Question Text","description":"Percentage of Follicular Component in DLBCL","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2605BA7-8DB0-4407-E040-BB89AD4335A4","latestVersionIndicator":"Yes","beginDate":"2011-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-05-03","modifiedBy":"TSESU","dateModified":"2018-07-13","changeDescription":"Created for TCGA per request by B.McClure-Shimel. mc 5/3/11  Released per approval by B. McClure-Shimel. mc 5/12/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}